Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.
Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.
The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.
Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.
Price: 46.30, Change: +0.66, Percent Change: +1.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.